Information provided in the product description is from published literature. Due to the nature of scientific experimentation, your results (e.g., selectivity and effective concentrations) or specific application for this product may differ. If you have questions about how this product fits your application, please contact our technical support staff.
Visit our FAQ
Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888
Product Categories
Research Area
Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

IPN60090 is an inhibitor of glutaminase 1 (GLS1; IC50 = 0.031 µM for the glutaminase C isoform).1 It is selective for GLS1 over GLS2 (IC50 = >50 µM), as well as panels of 80 ion channels and receptors and 97 kinases at 10 µM. IPN60090 also binds to zinc finger SWIM domain-containing protein 4 (ZSWIM4; Kd = 2.98 µM).2 It decreases the viability of A549 non-small cell lung cancer (NSCLC) cells (IC50 = 26 nM) and decreases glycine levels in OVCAR-8 and SKOV3 ovarian cancer cells.1,2 IPN60090 (30 mg/kg, p.o.), in combination with the DNA-crosslinking agent carboplatin (Item No. 13112), decreases tumor weight and volume in a SKOV3 mouse xenograft model.2
WARNING This product is not for human or veterinary use.
1. Discovery of IPN60090, a clinical stage selective glutaminase-
2. ZSWIM4 inhibition improves chemosensitivity in epithelial ovarian cancer cells by suppressing intracellular glycine biosynthesis. J. Transl. Med. 22(1), 192 (2021).